Driving innovation and fostering collaboration to advance the development and clinical research of next-generation human serum albumin

Jidong JIA; Junqi NIU

doi:10.12449/JCH250301

Volume 41 Issue 3

Mar. 2025

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(3): 401-403

PDF( 508 KB)

Driving innovation and fostering collaboration to advance the development and clinical research of next-generation human serum albumin

DOI: 10.12449/JCH250301

Jidong JIA^{1
,
,
,},
Junqi NIU²

1.
Liver Research Center，Beijing Friendship Hospital，Capital Medical University，Beijing 100050，China
2.
Department of Hepatology，The First Hospital of Jilin University，Center of Infectious Diseases and Pathogen Biology，Changchun 130021，China

More Information

Corresponding author: JIA Jidong， jia_jd@ccmu.edu.cn （ORCID： 0000-0002-4673-8890）
Received Date: 2025-02-26
Accepted Date: 2025-03-10
Published Date: 2025-03-25

Abstract

Abstract

Albumin is the most abundant protein in human plasma， and in addition to the function of maintaining plasma colloid osmotic pressure， it also has the functions of material transport， detoxification， maintaining vascular integrity， antioxidation， anti-inflammation， and immune modulation. In the field of liver disease， albumin is mainly used to prevent circulatory dysfunction after large-volume paracentesis and treat cirrhotic hypoalbuminemia and ascites， spontaneous bacterial peritonitis， and hepatorenal syndrome. The development of recombinant human serum albumin helps to reduce the potential biosafety risks of human serum albumin products and the disadvantages of relying heavily on import. Due to the lack of reference to the results of pivotal clinical trials of marketed human albumin products， there are still various challenges in the design， implementation， and evaluation of clinical trials of human albumin. Therefore， experts in pharmaceutical enterprises， clinical medicine， methodology， and evaluation/supervision are needed to be pragmatic， innovative and collaborative.
- Albumins,
- Recombinant Human Serum Albumin,
- Liver Cirrhosis,
- Clinical Trial

FullText(HTML)

References(20)

References

[1]	CARACENI P, O’BRIEN A, GINES P. Long-term albumin treatment in patients with cirrhosis and ascites[J]. J Hepatol, 2022, 76( 6): 1306- 1317. DOI: 10.1016/j.jhep.2022.03.005.
[2]	MURPHY G, BRAYDEN DJ, CHEUNG DL, et al. Albumin-based delivery systems: Recent advances, challenges, and opportunities[J]. J Control Release, 2025, 380: 375- 395. DOI: 10.1016/j.jconrel.2025.01.035.
[3]	FEATHERSTONE PJ, BALL CM. The development of albumin solutions in the second world war[J]. Anaesth Intensive Care, 2023, 51( 4): 236- 238. DOI: 10.1177/0310057X231174704.
[4]	FEATHERSTONE PJ, BALL CM. From conflict to controversy: The use and abuse of human albumin solutions after the Second World War[J]. Anaesth Intensive Care, 2023, 51( 6): 368- 371. DOI: 10.1177/0310057X231199368.
[5]	SANER FH, STUEBEN BO, HOYER DP, et al. Use or misuse of albumin in critical ill patients[J]. Diseases, 2023, 11( 2): 68. DOI: 10.3390/diseases11020068.
[6]	WIEDERMANN CJ, ZABOLI A, TURCATO G. Synthesis of expert opinions on fluid management in severe sepsis: A contextual review of human albumin and crystalloids[J]. Heart Lung, 2025, 70: 339- 359. DOI: 10.1016/j.hrtlng.2025.01.010.
[7]	GARCIA-TSAO G, ABRALDES JG, RICH NE, et al. AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: Expert review[J]. Gastroenterology, 2024, 166( 1): 202- 210. DOI: 10.1053/j.gastro.2023.10.016.
[8]	CARACENI P, RIGGIO O, ANGELI P, et al. Long-term albumin administration in decompensated cirrhosis(ANSWER): An open-label randomised trial[J]. Lancet, 2018, 391( 10138): 2417- 2429. DOI: 10.1016/S0140-6736(18)30840-7.
[9]	CHINA L, FREEMANTLE N, FORREST E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis[J]. N Engl J Med, 2021, 384( 9): 808- 817. DOI: 10.1056/NEJMoa2022166.
[10]	SOLÀ E, SOLÉ C, SIMÓN-TALERO M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial[J]. J Hepatol, 2018, 69( 6): 1250- 1259. DOI: 10.1016/j.jhep.2018.08.006.
[11]	CHRIS RUNKEN M, CARACENI P, FERNANDEZ J, et al. The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain[J]. Health Econ Rev, 2019, 9( 1): 22. DOI: 10.1186/s13561-019-0237-7.
[12]	HASAN I, MURTI IS, BAYUPURNAMA P, et al. Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings[J]. Drugs Context, 2024, 13: 2024-2021- 1. DOI: 10.7573/dic.2024-1-1.
[13]	BALDASSARRE M, NALDI M, ZACCHERINI G, et al. Determination of effective albumin in patients with decompensated cirrhosis: Clinical and prognostic implications[J]. Hepatology, 2021, 74( 4): 2058- 2073. DOI: 10.1002/hep.31798.
[14]	ERSTAD BL. Introduction to the concept of effective albumin concentration[J]. Am J Health Syst Pharm, 2024, 82( 1): 5- 11. DOI: 10.1093/ajhp/zxae232.
[15]	CHEN Z, HE Y, SHI B, et al. Human serum albumin from recombinant DNA technology: Challenges and strategies[J]. Biochim Biophys Acta, 2013, 1830( 12): 5515- 5525. DOI: 10.1016/j.bbagen.2013.04.037.
[16]	ABRALDES JG, TREBICKA J, CHALASANI N, et al. Prioritization of therapeutic targets and trial design in cirrhotic portal hypertension[J]. Hepatology, 2019, 69( 3): 1287- 1299. DOI: 10.1002/hep.30314.
[17]	TORP N, ISRAELSEN M, COENRAAD M, et al. Personalised human albumin in patients with cirrhosis and ascites: Design and rationale for the ALB-TRIAL- a randomised clinical biomarker validation trial[J]. BMJ Open, 2024, 14( 2): e079309. DOI: 10.1136/bmjopen-2023-079309.
[18]	GENTILINI P, CASINI-RAGGI V, DI FIORE G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: Results of a randomized, controlled trial[J]. J Hepatol, 1999, 30( 4): 639- 645. DOI: 10.1016/s0168-8278(99)80194-9.
[19]	CARACENI P, ANGELI P, PRATI D, et al. AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: A 2020 update[J]. Blood Transfus, 2021, 19( 1): 9- 13. DOI: 10.2450/2020.0414-20.
[20]	KALO E, READ S, BAIG A, et al. Efficacy of albumin use in decompensated cirrhosis and real-world adoption in Australia[J]. JGH Open, 2024, 8( 9): e70029. DOI: 10.1002/jgh3.70029.

Relative Articles

[1]	Yaxin LI, Huiguo DING. The application of human serum albumin in liver cirrhosis and its complications[J]. Journal of Clinical Hepatology, 2025, 41(3): 409-414. doi: 10.12449/JCH250303
[2]	Jingjing WANG, Ligai LIU, Wen XIE. A re-understanding of the physiological function of albumin[J]. Journal of Clinical Hepatology, 2025, 41(3): 404-408. doi: 10.12449/JCH250302
[3]	Yuanyuan KONG, Chen YAO, Jidong JIA. Statistical considerations in the design of albumin clinical trials[J]. Journal of Clinical Hepatology, 2025, 41(3): 420-423. doi: 10.12449/JCH250305
[4]	Qichao GE, Lungen LU. Value of liver biopsy in the diagnosis and clinical trial of non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2024, 40(11): 2288-2292. doi: 10.12449/JCH241124
[5]	Zhaohui BAI, Yongping YANG, Li YANG, Xingshun QI. An excerpt of use of albumin infusion for cirrhosis-related complications: an international position statement in 2022[J]. Journal of Clinical Hepatology, 2023, 39(8): 1817-1818. doi: 10.3969/j.issn.1001-5256.2023.08.008
[6]	Center for Drug Evaluation, National Medicine Products Administration. Guidelines for identification, management, and assessment of drug-induced liver injury in clinical trials[J]. Journal of Clinical Hepatology, 2023, 39(8): 1811-1816. doi: 10.3969/j.issn.1001-5256.2023.08.007
[7]	Yingshuo HUANG, Wei WEI, Xiaofei TONG, Yameng SUN, Jianxiong ZHANG, Ruihua DONG, Jidong JIA, Hong YOU. Clinical trial protocols of new drugs for nonalcoholic steatohepatitis: A systematic review[J]. Journal of Clinical Hepatology, 2022, 38(4): 798-804. doi: 10.3969/j.issn.1001-5256.2022.04.012
[8]	Hui LIU, Fengmin LU, Jutao GUO. Mechanism of action, clinical research and development, and application prospect of hepatitis B virus core protein allosteric modulators[J]. Journal of Clinical Hepatology, 2022, 38(8): 1726-1732. doi: 10.3969/j.issn.1001-5256.2022.08.005
[9]	Ziming AN, Qin FENG. Magnetic resonance imaging-proton density fat fraction: A potential surrogate endpoint for nonalcoholic steatohepatitis clinical trials[J]. Journal of Clinical Hepatology, 2021, 37(6): 1445-1448. doi: 10.3969/j.issn.1001-5256.2021.06.047
[10]	Huiying RAO, Lai WEI. Interpretation of clinical trial guidelines for nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2021, 37(6): 1245-1248. doi: 10.3969/j.issn.1001-5256.2021.06.002
[11]	Deng Rui, Sun Jian. An excerpt of guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference[J]. Journal of Clinical Hepatology, 2020, 36(3): 522-526. doi: 10.3969/j.issn.1001-5256.2020.03.009
[12]	Yang Jun, Ning QiQi, Wu Jing, Li Juan, Zhu YueKe, Yu HongWei, Meng QingHua, Hu ZhongJie. Clinical effect of human serum albumin versus artificial colloidal fluid in patients with cirrhotic ascites undergoing drainage:A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(1): 82-86. doi: 10.3969/j.issn.1001-5256.2019.01.015
[13]	Mao YiMin. Important issues in protocol design of exploratory and confirmatory clinical trials of new drugs for nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2018, 34(12): 2509-2514. doi: 10.3969/j.issn.1001-5256.2018.12.005
[14]	Jiang LiNa, Zhao JingMin. A clinical trial on the follow-up of nonalcoholic fatty liver disease: An evaluation of pathological endpoint[J]. Journal of Clinical Hepatology, 2018, 34(12): 2505-2508. doi: 10.3969/j.issn.1001-5256.2018.12.004
[15]	Ju HuanJia, Shi JunPing. Clinical trials tracking nonalcoholic fatty liver disease: Noninvasive measures[J]. Journal of Clinical Hepatology, 2018, 34(12): 2501-2504. doi: 10.3969/j.issn.1001-5256.2018.12.003
[16]	Mao YiMin. Clinical trials of investigational new drugs for nonalcoholic steatohepatitis:challenges in design and practice[J]. Journal of Clinical Hepatology, 2017, 33(12): 2292-2295. doi: 10.3969/j.issn.1001-5256.2017.12.007
[17]	Ji ShiYu, Hu Yi. Clinical effect of albumin-bound paclitaxel in treatment of advanced primary liver cancer[J]. Journal of Clinical Hepatology, 2016, 32(10): 1911-1915. doi: 10.3969/j.issn.1001-5256.2016.10.017
[18]	Huang DongHai, Shi JianShe, Zhang ChengHua. Usage analysis of human serum albumin in patients with liver cancer and liver cirrhosis after hepatectomy[J]. Journal of Clinical Hepatology, 2015, 31(6): 910-914. doi: 10.3969/j.issn.1001-5256.2015.06.020
[19]	Ji Guang. Relevant issues concerning clinical trials of traditional Chinese medicine treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2014, 30(4): 299-302. doi: 10.3969/j.issn.1001-5256.2014.04.003
[20]	Chen Si, Sun ZhangYu, Zhang ZhiHao, Wang YingYing. Therapeutic effect of terlipressin combined with albumin in 24 patients with hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2014, 30(8): 782-784. doi: 10.3969/j.issn.1001-5256.2014.08.021

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (105) PDF downloads(30)

Driving innovation and fostering collaboration to advance the development and clinical research of next-generation human serum albumin

DOI: 10.12449/JCH250301

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Driving innovation and fostering collaboration to advance the development and clinical research of next-generation human serum albumin

DOI: 10.12449/JCH250301

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content